In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $6.44.
According to TipRanks, Harrison is a 5-star analyst with an average return of 30.7% and a 68.42% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Outlook Therapeutics, Prometheus Biosciences, and United Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Liquidia Technologies with a $13.75 average price target, representing an 113.51% upside. In a report released on January 9, Needham also maintained a Buy rating on the stock with a $16.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
LQDA market cap is currently $416M and has a P/E ratio of -7.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
Read More on LQDA:
- Liquidia enters Revenue Interest Financing Agreement with HealthCare Royalty
- Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
- Liquidia enters Treprostinil Injection collaboration with Sandoz, Mainbridge
- Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
